Tübingen, Germany: CeGaT, a global provider of sequencing services for research, clinical studies, and human genetic diagnostics, is investing in new NovaSeq 6000 sequencing systems from Illumina. This acquisition is a strategically important move given CeGaT’s rapid corporate growth.

CeGaT has acquired a sixth and seventh NovaSeq 6000 to meet the increasing demand for sequencing and genetic analyses also in the future. These sequencers are Illumina’s most powerful next-generation sequencing platforms. They can be used, for example, to analyze genomes, meaning the entire genetic information of an individual, in the shortest possible time. With a total of seven instruments, CeGaT can generate data volumes of up to 42 terabytes in less than two days. CeGaT continuously invests in state-of-the-art equipment and can thus offer its international customers short analysis times and a steadily growing portfolio of sequencing services.

Largest owner-managed sequencing service provider in Europe

Dr. Jiri Ködding, Director Operations at CeGaT, is proud of the development: “We already acquired our fourth and fifth NovaSeq 6000 two years ago. This has enabled us to sequence 9,000 to 14,000 additional genomes per year. Fortunately, the demand for our sequencing services is increasing so strongly that we are again reaching capacity limits. Our ambition is and remains to make next-generation sequencing accessible to all research groups. To this end, we are now creating further capacity, making us the largest privately managed sequencing provider in Europe.”

Millions invested in the Tübingen Technology Park

The investments in the future are not limited to high-throughput sequencers. CeGaT has been constructing an annex building since 2021, for which 20 to 25 million euros have been budgeted. Completion is expected in 2023. Additional laboratory and office space will be built on three floors to provide space for 400 to 500 employees. It was only in 2014 that CeGaT moved from rented premises to its own newly built company building in Tübingen, Paul-Ehrlich-Strasse.

About CeGaT

CeGaT is a global provider of genetic analyses for a wide range of medical, research, and pharmaceutical applications.

Founded in 2009 in Tübingen, Germany, the company combines state-of-the-art sequencing technology with medical expertise – with the aim of identifying the genetic causes of diseases and supporting patient care. For researchers and pharmaceutical companies, CeGaT offers a broad portfolio of sequencing services and tumor analyses. CeGaT generates the data basis for clinical studies and medical innovations and drives science forward with its own insights.

The owner-managed company stands for independence, comprehensive personal customer service, and outstanding quality. CeGaT’s laboratory is accredited according to CAP/CLIA, DIN EN ISO 15189, and DIN EN ISO 17025 and thus meets the highest international standards. To obtain first-class results, all processes are carried out in-house under scientific supervision.